Vaccines Market 2020 By Industry Trends & Regional Forecast To 2026

Vaccines Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

Vaccines can be touted as an effectual and clinically-proven, preventive treatment solution. Higher prevalence of viral infections such as COVID-19 and intense R&D carried out for innovative advances will boost the global demand for vaccines over the present and coming years. Vaccine immunization programs regulated in the U.S. are currently focused on offering solutions for over 17 preventable diseases.

A surge in government investments and awareness initiatives along with the jump in immunization resulting from decreased indirect costs of diseases and direct healthcare costs will drive the demand for vaccines. There is an augmenting focus on the development as well as the awareness of preventable vaccines. The National Immunization Program (NIP) was launched in 1997 to limit the prevalence of preventable diseases by magnifying the national immunization coverage.

Request for a sample copy of this report @

However, infectious diseases are leading to a higher rate of disability, illness, and death, albeit the growth in the vaccination coverage. This is likely to attract multiple growth opportunities for vaccine vendors to offer efficient solutions against these diseases. Reportedly, vaccines market size will globally record an exponential growth rate through 2026.

Global vaccines market share from the adult segment reached USD 17.5 billion in remuneration in 2019 due to the intensifying risk of infections as well as comorbidities in these individuals. The Centers for Disease Control and Prevention estimated that more than 300,000 people are diagnosed with pneumococcal pneumonia annually leading to 150,000 hospitalizations, while the human papillomavirus that affects adults registers 27,000 cancer cases per year. The consistent prevalence of these ailments will bolster the supply and consumption of the vaccines in the coming years.

Demand for hepatitis vaccines will witness significant expansion and the market pegged to register a 12.9% CAGR through 2026, due to the growing episodes of the infection affecting a larger population base as well as the inclining demand and access to the vaccine. As per estimates, over 1.4 million people are infected with hepatitis and other related conditions like liver cancer across the U.S.

A recombinant vaccine technology comprises non-replicating plasmids that instigate a strong long-term immune response towards pathogens. They eliminate the risk of toxic reversals and assist in the co-purification of undesired contaminants. The recombinant vaccines industry brought 21% of the overall global share in 2019. The high adoption of the vaccine can be attributed to the consistent R&D carried out in recombinant DNA technology.

Europe can be considered a major consumer for various types of vaccines considering the rise in the R&D activities and mounting healthcare spending across the region. The regional market accounted for 28% of the global revenue in 2019 and is projected to amass a substantial share in the next few years. Regional manufacturers are consistently focused on developmental activities to offer effective vaccines in the present COVID-19 period. 

Request for customization @

There is also a growing effort by the government to effectively manage the production and distribution of vaccines. For instance, AstraZeneca, a British pharma company, partnered with the European Commission in August 2020 to supply over 400 million doses of its AZD1222 COVID-19 vaccine to the regional population.

Vaccine suppliers are working on employing numerous strategies like product innovations, associations and commercialization of newer vaccines to expand their global presence. For instance, Sanofi and GlaxoSmithKline (GSK) entered an agreement in April 2020, for medical advancement in the development of the COVID-19 vaccine. Abbott Laboratories, Merck, Johnson & Johnson and Pfizer are some of the other global firms.  

Partial Chapter of the Table of Content 

Chapter 4. Vaccines Market, By Age Group

4.1. Key segment trends

4.2. Pediatric

4.2.1.  Market size, by region, 2015 - 2026 (USD Million)

4.3. Adult

4.3.1.  Market size, by region, 2015 - 2026 (USD Million)

Chapter 5. Vaccines Market, By Disease

5.1. Key segment trends

5.2. Cancer

5.2.1.  Market size, by region, 2015 - 2026 (USD Million)

5.3. Hepatitis

5.3.1.  Market size, by region, 2015 - 2026 (USD Million)

5.4. Pneumococcal disease

5.4.1.  Market size, by region, 2015 - 2026 (USD Million)

5.5. DTP

5.5.1.  Market size, by region, 2015 - 2026 (USD Million)

5.6. Dengue

5.6.1.  Market size, by region, 2015 - 2026 (USD Million)

5.7. Influenza

5.7.1.  Market size, by region, 2015 - 2026 (USD Million)

5.8. Human papilloma virus

5.8.1.  Market size, by region, 2015 - 2026 (USD Million)

5.9. Meningococcal disease

5.9.1.  Market size, by region, 2015 - 2026 (USD Million)

5.10.  Polio

5.10.1. Market size, by region, 2015 - 2026 (USD Million)

5.11.  Rotavirus

5.11.1. Market size, by region, 2015 - 2026 (USD Million)

5.12.  Others

5.12.1. Market size, by region, 2015 - 2026 (USD Million) 

Browse full table of contents (TOC) of this report @